Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Multiple Gestation Study

NCT02278536 · View on ClinicalTrials.gov ↗

Study Summary

The objectives of the clinical study are to demonstrate the accuracy of our new NATUS diagnostic method to determine the genetic health of the developing fetuses in a multiple gestation pregnancy from a maternal blood sample. The long term goal of this study will be the development of a method of minimally invasive prenatal diagnosis that has a higher sensitivity and lower false positive rate in the intended population (e.g. multiple gestation pregnancies) than any currently available screening tests. This will result in fewer unnecessary amniocenteses and CVS procedures, which are associated with a risk of miscarriage.

Study Locations (8)

California

  • Natera, Inc. — San Carlos
  • San Diego Perinatal Center — San Diego

Texas

  • Office of Dr. Robert Carpenter — Houston
  • Houston Perinatal Associates — Houston

New York

  • Carnegie Hill Imaging for Women — New York

North Carolina

  • Lyndhurst Clinical Research — Winston-Salem

Other

  • Bangalore Fetal Medicine Centre — Bangalore

Selangor

  • Fetal Medicine & Gynaecology Centre — Petaling Jaya

Trial Details

FieldValue
Enrollment Target 354 participants
Start Date 2013-03
Est. Completion 2019-03

Sponsor

Natera

40 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02278536

The ClinicalTrials.gov registry entry for NCT02278536 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 354 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Natera, which has 40 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Trisomy 21 appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02278536 reports 8 study locations spanning 6 distinct geographic areas — top geographies include California, Texas, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02278536 about?

NCT02278536 is a clinical study titled "Multiple Gestation Study". The objectives of the clinical study are to demonstrate the accuracy of our new NATUS diagnostic method to determine the genetic health of the developing fetuses in a multiple gestation pregnancy from a maternal blood sample. The long term goal of this study will be the development of a method of mi...

What is the current status of trial NCT02278536?

This trial is currently completed. The enrollment target is 354 participants. The study started on 2013-03. Estimated completion is 2019-03.

What conditions does trial NCT02278536 study?

This clinical trial studies the following conditions: Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT02278536?

This trial is sponsored by Natera, which has 40 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02278536 being conducted?

This trial has 8 study locations across California, New York, North Carolina, Texas, Selangor. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial